ArticleActa medica Philippina2025
Clinical Features and Outcomes of Ocular Myasthenia Gravis in a Tertiary Philippine Hospital.
Article in Acta medica Philippina, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To describe the clinical profile and outcomes of a series of adult patients diagnosed with ocular myasthenia gravis and to evaluate the potential factors affecting the risk of generalization. Methods: This retrospective cohort study involved a medical chart review of adult patients seen from 2012 to 2019 at the neuro-ophthalmology clinic of a tertiary Philippine hospital with a clinical diagnosis of ocular myasthenia gravis supported by serologic, electrophysiologic, or pharmacologic test results. Outcomes of interest were complete stable remission, pharmacologic remission, minimal manifestations, and generalization. Kaplan-Meier method and log-rank test were used to analyze the probability of generalization. Results: The study sample consisted of 16 patients. The female to male ratio was 3:1. Mean age at symptom onset was 39 years. All patients received pharmacologic treatment, while two patients underwent thymectomy. No patient had remission as of last follow-up. Three patients had conversion of ocular myasthenia gravis to generalized myasthenia gravis. Mean time from symptom onset to generalization was 10.7 months. The generalization curves of patients who were symptomatic for less than two years and those who were symptomatic for at least two years prior to consult were significantly different ( Conclusion: In this single-center study, there was female predominance among adult patients diagnosed with ocular myasthenia gravis. The incidence of generalization was 4 per 100 person-years while the 2-year probability of generalization was 30%. Further study is needed in order to determine the factors affecting the risk of generalization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.